Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer

August 27th 2019

Although CDK4/6 inhibitors are remaking the treatment landscape for patients with estrogen receptor–positive metastatic breast cancer, questions about optimal sequencing and strategies for attacking resistance and progression remain unsettled.

Fitness Assessments Should Be Integrated Into Care for Older Patients With Breast Cancer

August 27th 2019

Treatment decisions for older patients with breast cancer should be individualized based on the fitness and frailty of the patient, making the use of geriatric assessment tools an essential element of care, according to Armin Shahrokni, MD, MPH.

New Strategies Are Evolving for Breast Cancer Brain Metastases

August 27th 2019

A greater focus on studying mechanisms for therapies that penetrate the blood–tumor barrier and the expansion of clinical trial eligibility criteria are opening the door for advancements that may help patients with metastatic breast cancer that has spread to the brain, according to Carey K. Anders, MD.

First Multilingual App for Breast Exam Aims to Improve Early Cancer Detection

August 25th 2019

Pink Luminous Advocacy Project's Breast Awareness app is the first multilingual, unisex breast self-examination application.

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

August 23rd 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Alpelisib Arrives as New Targeted Option for Breast Cancer Subgroup

August 20th 2019

Dejan Juric, MD, discusses the significance of the alpelisib approval and the importance of developing a plan for the management of adverse events.

Resistance Shapes New Therapeutic Options in ER-Positive Breast Cancer

August 19th 2019

Although hormonal manipulation was an established part of breast cancer treatment long before the underlying biology of the disease was characterized, advancements in the understanding of estrogen receptor signaling are rapidly changing the therapeutic landscape.

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer

August 16th 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.

Pivotal Trials With CDK4/6, PI3K Inhibitors Propel Progress in HR+ Breast Cancer

August 15th 2019

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

Top Breast Cancer Oncologists Highlight Their Ongoing Research

August 8th 2019

Experts from Emory University School of Medicine, Massachusetts General Hospital, and Hospital of the University of Pennsylvania, highlight the exciting research being conducted at their respective institutions.

Encequidar Plus Oral Paclitaxel Increases Response Over IV Paclitaxel in Breast Cancer

August 8th 2019

The combination of encequidar and oral paclitaxel improved the overall response rate compared with IV paclitaxel in patients with metastatic breast cancer.

Genomic Assays Answer Adjuvant Questions in Early-Stage Breast Cancer

August 7th 2019

Alan B. Astrow, MD, discusses the latest efforts to personalize patient care in early-stage, HR-positive, HER2-negative breast cancer.

CDK4/6 Inhibitors Showing Survival Gains in Metastatic HR+ Breast Cancer

August 6th 2019

Payal D. Shah, MD, discusses the paradigm shift in metastatic HR-positive, HER2-negative breast cancer, now largely defined by the use of CDK4/6 inhibitors.

IMpassion130 Trial Takes Immunotherapy to Forefront of TNBC

August 6th 2019

Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.

Dr. Andreopoulou on the Impact of Immunotherapy in TNBC

August 5th 2019

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Genetic Variant Causes Susceptibility to TNBC in African Subpopulations

August 2nd 2019

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

August 1st 2019

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Immunotherapy Builds Momentum in Metastatic TNBC

July 31st 2019

Aditya Bardia, MD, MPH, discusses the recent momentum in metastatic triple-negative breast cancer treatment.

Ribociclib Improves Survival in Postmenopausal Women With Advanced Breast Cancer

July 31st 2019

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly improved overall survival as a first- or second-line treatment for postmenopausal women with hormone receptor–positive/HER2-negative breast cancer, according to findings from a preplanned interim analysis of the phase III MONALEESA-3 trial.